Ocugen, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $434.1M
- Price
- $1.27
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.78%
- Volume
- 4.5M
About
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Quick stats
Shares outstanding339.1M
Computed float322.0M
Float / shares95.0%
Cash runway (months)1.5
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001372299
Websitehttps://www.ocugen.com
AI Summary
AI-generated1/26
majorbullishearnings
Ocugen Provides Business Update with Second Quarter 2026 Financial Results
Ocugen reported Q2 2026 financial results highlighted by FDA clearance to initiate the Phase 3 ArMaDa3 trial for OCU410 in geographic atrophy and receipt of Regenerative Medicine Advanced Therapy (RMAT) designation.
The company strengthened its balance sheet by closing a $130 million convertible senior notes offering, extending its cash runway into 2028 and using $32.7 million of proceeds to fully retire a high-interest loan from Avenue Capital.
Operationally, Ocugen completed enrollment for its OCU400 trial in retinitis pigmentosa and its OCU410ST trial in Stargardt disease, with top-line data expected in the first and second quarters of 2027, respectively.
Red flags
- Net loss per share widened to $0.07 from $0.05 in the prior year period
- Convertible notes offering introduces potential future dilution
- Accumulated deficit increased to $(452.1) million